Literature DB >> 19031458

Diverse IgG subclass responses to adeno-associated virus infection and vector administration.

Samuel L Murphy1, Hojun Li, Federico Mingozzi, Denise E Sabatino, Daniel J Hui, Shyrie A Edmonson, Katherine A High.   

Abstract

Humoral immune responses occur following exposure to Adeno-associated virus (AAV) or AAV vectors. Many studies characterized antibody responses to AAV, but human IgG subclass responses to AAV have not been previously described. In this study, IgG subclass responses were examined in serum samples of normal human subjects exposed to wild-type AAV, subjects injected intramuscularly with AAV vectors and subjects injected intravascularly with AAV vectors. A diversity of IgG subclass responses to AAV capsid were found in different subjects. IgG1 was found to be the dominant response. IgG2, IgG3, and IgG4 responses were also observed in most normal human subjects; IgG2 and IgG3 each represented the major fraction of total anti-AAV capsid IgG in a subset of normal donors. Subjects exposed to AAV vectors showed IgG responses to AAV capsid of all four IgG subclasses. IgG responses to AAV capsid in clinical trial subjects were inversely proportional to the level of pre-existing anti-AAV antibody and independent of the vector dose. The high levels of anti-AAV capsid IgG1 can mask differences in IgG2, IgG3, and IgG4 responses that were observed in this study. Analysis of IgG subclass distribution of anti-AAV capsid antibodies indicates a complex, non-uniform pattern of responses to this viral antigen. J. Med. Virol. 81:65-74, 2009. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19031458      PMCID: PMC2782623          DOI: 10.1002/jmv.21360

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  35 in total

1.  Subclass restriction of immunoglobulin G in liver cirrhosis.

Authors:  S M Akbar; M Onji; T Masumoto; Y Ohta
Journal:  J Gastroenterol Hepatol       Date:  1990 Nov-Dec       Impact factor: 4.029

2.  Herpes simplex virus-specific IgM, IgA and IgG subclass antibody responses in primary and nonprimary genital herpes patients.

Authors:  M Hashido; T Kawana
Journal:  Microbiol Immunol       Date:  1997       Impact factor: 1.955

3.  Epidemiology of adenovirus-associated virus infection in a nursery population.

Authors:  N R Blacklow; M D Hoggan; A Z Kapikian; J B Austin; W P Rowe
Journal:  Am J Epidemiol       Date:  1968-11       Impact factor: 4.897

4.  Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans.

Authors:  Oscar Norbeck; Adiba Isa; Christoph Pöhlmann; Kristina Broliden; Victoria Kasprowicz; Paul Bowness; Paul Klenerman; Thomas Tolfvenstam
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

5.  Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle.

Authors:  N Chirmule; W Xiao; A Truneh; M A Schnell; J V Hughes; P Zoltick; J M Wilson
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 6.  Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?

Authors:  K High
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

Review 7.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

8.  A seroepidemiologic study of adenovirus-associated virus infection in infants and children.

Authors:  N R Blacklow; M D Hoggan; M S Sereno; C D Brandt; H W Kim; R H Parrott; R M Chanock
Journal:  Am J Epidemiol       Date:  1971-10       Impact factor: 4.897

9.  CD8(+) T-cell responses to adeno-associated virus capsid in humans.

Authors:  Federico Mingozzi; Marcela V Maus; Daniel J Hui; Denise E Sabatino; Samuel L Murphy; John E J Rasko; Margaret V Ragni; Catherine S Manno; Jurg Sommer; Haiyan Jiang; Glenn F Pierce; Hildegund C J Ertl; Katherine A High
Journal:  Nat Med       Date:  2007-03-18       Impact factor: 53.440

10.  Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.

Authors:  Amit C Nathwani; John T Gray; Catherine Y C Ng; Junfang Zhou; Yunyu Spence; Simon N Waddington; Edward G D Tuddenham; Geoffrey Kemball-Cook; Jenny McIntosh; Mariette Boon-Spijker; Koen Mertens; Andrew M Davidoff
Journal:  Blood       Date:  2005-12-01       Impact factor: 22.113

View more
  42 in total

1.  Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.

Authors:  Carole E Harbison; Wendy S Weichert; Brittney L Gurda; John A Chiorini; Mavis Agbandje-McKenna; Colin R Parrish
Journal:  J Gen Virol       Date:  2011-11-09       Impact factor: 3.891

2.  Gene-based passive antibody protection from HIV.

Authors:  Margaret A Liu
Journal:  Nat Biotechnol       Date:  2012-02-08       Impact factor: 54.908

Review 3.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

4.  Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.

Authors:  Chengwen Li; Nina Diprimio; Dawn E Bowles; Matthew L Hirsch; Paul E Monahan; Aravind Asokan; Joseph Rabinowitz; Mavis Agbandje-McKenna; R Jude Samulski
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

Review 5.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

6.  The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques.

Authors:  Lili Wang; Roberto Calcedo; Huan Wang; Peter Bell; Rebecca Grant; Luk H Vandenberghe; Julio Sanmiguel; Hiroki Morizono; Mark L Batshaw; James M Wilson
Journal:  Mol Ther       Date:  2009-11-03       Impact factor: 11.454

7.  AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.

Authors:  Julie M Crudele; Jonathan D Finn; Joshua I Siner; Nicholas B Martin; Glenn P Niemeyer; Shangzhen Zhou; Federico Mingozzi; Clinton D Lothrop; Valder R Arruda
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

Review 8.  Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.

Authors:  Majid Lotfinia; Meghdad Abdollahpour-Alitappeh; Behzad Hatami; Mohammad Reza Zali; Morteza Karimipoor
Journal:  Clin Exp Med       Date:  2019-05-03       Impact factor: 3.984

Review 9.  Progress and prospects: immune responses to viral vectors.

Authors:  S Nayak; R W Herzog
Journal:  Gene Ther       Date:  2009-11-12       Impact factor: 5.250

10.  Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1.

Authors:  Declan Madsen; Emma R Cantwell; Timothy O'Brien; Patricia A Johnson; Bernard P Mahon
Journal:  J Gen Virol       Date:  2009-07-29       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.